BMYBristol-Myers SquibbFinished
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Advanced Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 1/2
- Patients
- 219 (final count)
- Started
- Sep 6, 2019
- Main results expected
- Aug 31, 2024
- Fully finished
- Aug 31, 2024
- Results posted
- Jan 20, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety Related Events for Cohorts 1A, 1B and 2B.
Measured over: approximately 6 months
Dose Limiting Toxicities Cohorts 1A, 1B and 2B.
Measured over: approximately 5 weeks
Objective Response Rate by BICR in Cohort 2C
Measured over: approximately 2.15 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03994601 · record last updated 2026-01-20 · checked 2026-11-09 15:42 UTC